The Hindu Business Line : Ranbaxy in pact with Eurodrug for asthma drug

Ranbaxy Laboratories Ltd has said it had entered into an in-licensing agreement with Netherlands-based Eurodrug Laboratories for introducing the asthma product `Doxophylline' in India.

Doxophylline, a Xanthine bronchodilator developed in collaboration with many European medical centres, will be introduced for the first time in India under the brand name "Synasma", the company said in a statement.

Commenting on the development, Ranbaxy's Regional Director India and West Asia, Mr Sanjeev I. Dani, said: "It is our strategic intent to in-license differentiated products for the Indian market in the post-patent era and this drug augments the company's position in the fast growing asthma segment."

The drug is indicated for chronic-bronchitis, asthma and chronic obstructive pulmonary disease (COPD) and is claimed to be superior to available Xanthine analogues, like Theophylline and Aminophylline. Eurodurg has been successfully marketing this medicine in Europe, Latin America and few Asian markets like Korea, the Philippines and Thailand.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Jain Granites bags orders worth Rs 9.65 cr

Pitti Laminations plans pref offer

Bajaj Auto Finance plans rights offer

ORG Informatics eyes acquisitions

Jindal Steel to revamp foreign loan portfolio

Govt approves merger of MEL with SAIL

Strides acquires Warsaw-based sterile unit

Tatas pick Bengal for Rs 1-lakh car plant

AP CM to inaugurate mini steel plant

Forward Group to expand capacity; plans Chennai unit

HIL commissions asbestos plant in UP

Nepal's CG Foods plans new unit in Uttaranchal

HPCL revises cost of Vizag project

Ranbaxy in pact with Eurodrug for asthma drug

Elder Pharma ties up with Swedish co

Graphite India to firm up investment plans in July

Honda Siel's capacity expansion plan

IA hopeful of over Rs 100-cr net profit